Overview

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Status:
Completed
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
This study tested the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ISIS 443139 administered intrathecally to adult participants with early manifest Huntington's Disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.